RenovoRx, a biopharmaceutical company headquartered in Silicon Valley, California, has developed a therapy platform targeting difficult-to-treat tumors. Targeted therapy via the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform safely and without transmission to non-targeted areas, is the primary focus.
RenovoRx's patent portfolio includes seven U.S. patents for its technology. The Company also has secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine including pancreatic cancer and bile duct cancer. The RenovoTAMP therapy is being studied in the Phase III TIGeR-PaC trial for the treatment of locally advanced pancreatic cancer.
RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.
Company profile
Ticker
RNXT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
271448452
RNXT stock data
Latest filings (excl ownership)
8-K
Other Events
18 Jan 23
424B3
Prospectus supplement
22 Nov 22
EFFECT
Notice of effectiveness
22 Nov 22
EFFECT
Notice of effectiveness
22 Nov 22
CORRESP
Correspondence with SEC
18 Nov 22
CORRESP
Correspondence with SEC
18 Nov 22
UPLOAD
Letter from SEC
16 Nov 22
UPLOAD
Letter from SEC
16 Nov 22
8-K
RenovoRx Reports Third Quarter 2022 Financial Results
14 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.09 mm | 3.09 mm | 3.09 mm | 3.09 mm | 3.09 mm | 3.09 mm |
| Cash burn (monthly) | (no burn) | 1.22 mm | 720.33 k | 844.67 k | (no burn) | 138.25 k |
| Cash used (since last report) | n/a | 5.13 mm | 3.03 mm | 3.55 mm | n/a | 581.14 k |
| Cash remaining | n/a | -2.03 mm | 65.03 k | -457.62 k | n/a | 2.51 mm |
| Runway (months of cash) | n/a | -1.7 | 0.1 | -0.5 | n/a | 18.2 |
Institutional ownership, Q2 2022
27.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 13 |
| Opened positions | 1 |
| Closed positions | 3 |
| Increased positions | 5 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 8.52 mm |
| Total shares | 2.46 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Bank Of The West | 975.00 k | $1.93 mm |
| Kamran Najmabadi | 731.25 k | $3.54 mm |
| BSX Boston Scientific | 543.97 k | $2.63 mm |
| Cohen Lawrence B | 97.17 k | $192.00 k |
| BAC Bank Of America | 48.42 k | $96.00 k |
| SF Stifel Financial | 31.68 k | $63.00 k |
| Cambridge Investment Research Advisors | 14.40 k | $29.00 k |
| Vanguard | 10.82 k | $21.00 k |
| UBS UBS Group AG - Registered Shares | 6.22 k | $12.00 k |
| Tower Research Capital | 2.68 k | $5.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Nov 22 | Laurence Marton | Common Stock | Option exercise | Acquire M | No | No | 1.7 | 25,438 | 43.24 k | 25,438 |
| 3 Nov 22 | Laurence Marton | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.7 | 25,438 | 43.24 k | 0 |
| 1 Oct 22 | David Diamond | Stock Option Common Stock | Grant | Acquire A | No | No | 2.02 | 25,099 | 50.70 k | 25,099 |
| 1 Oct 22 | Kirsten Angela Macfarlane | Stock Option Common Stock | Grant | Acquire A | No | No | 2.02 | 25,099 | 50.70 k | 25,099 |
| 1 Oct 22 | Laurence Marton | Stock Option Common Stock | Grant | Acquire A | No | No | 2.02 | 25,099 | 50.70 k | 25,099 |
| 1 Oct 22 | Una S Ryan | Stock Option Common Stock | Grant | Acquire A | No | No | 2.02 | 25,099 | 50.70 k | 25,099 |
News
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
23 Jan 23
12 Health Care Stocks Moving In Monday's Intraday Session
23 Jan 23
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
19 Jan 23
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
19 Jan 23
12 Health Care Stocks Moving In Thursday's Pre-Market Session
19 Jan 23
Press releases
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
25 Jan 23
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment
18 Jan 23
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
5 Jan 23
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
15 Dec 22
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
17 Nov 22